RYBREVANT FASPRO Combination Shows High Response Rate in First-Line Advanced Head and Neck Cancer

New results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study indicate deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) combined with a PD-1 inhibitor and fixed-duration carboplatin chemotherapy. In patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (excluding HPV-associated oropharyngeal SCC), a confirmed overall response rate (ORR) of 77% was observed, including 14% complete responses. Tumor shrinkage occurred in all evaluable patients, with nearly two-thirds of responses ongoing at a median follow-up of 10.6 months. These findings were presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026.